Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/47812
Type
ArticleCopyright
Open access
Collections
- BA - IGM - Artigos de Periódicos [3332]
- IOC - Artigos de Periódicos [12133]
Metadata
Show full item record
BACILLUS CALMETTE–GUÉRIN IMMUNOTHERAPY FOR CANCER
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia Estrutural e Molecular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia Estrutural e Molecular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / Universidade Federal Fluminense. Instituto de Biologia. Laboratório de Virologia Molecular e Biotecnologia Marinha. Niterói, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / Faculdade de Medicina de Petrópolis. Petrópolis, RJ, Brasil.
Fundação Ataulpho de Paiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia Estrutural e Molecular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / Universidade Federal Fluminense. Instituto de Biologia. Laboratório de Virologia Molecular e Biotecnologia Marinha. Niterói, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / Faculdade de Medicina de Petrópolis. Petrópolis, RJ, Brasil.
Fundação Ataulpho de Paiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil.
Abstract
Bacillus Calmette–Guérin (BCG), an attenuated vaccine from Mycobacterium bovis, was initially developed as an agent for vaccination against tuberculosis. BCG proved to be the first successful immunotherapy against established human bladder cancer and other neoplasms. The use of BCG has been shown to induce a long-lasting antitumor response over all other forms of treatment against intermediate, non-invasive muscle bladder cancer Several types of tumors may now be treated by releasing the immune response through the blockade of checkpoint inhibitory molecules, such as CTLA-4 and PD-1. In addition, Toll-Like Receptor (TLR) agonists and BCG are used to potentiate the immune response against tumors. Studies concerning TLR-ligands combined with BCG to treat melanoma have demonstrated efficacy in treating mice and patients This review addresses several interventions using BCG on neoplasms, such as Leukemia, Bladder Cancer, Lung Cancer, and Melanoma, describing treatments and antitumor responses promoted by this attenuated bacillus. Of essential importance, BCG is described recently to participate in an adequate microbiome, establishing an effective response during cell-target therapy when combined with anti-PD-1 antibody, which stimulates T cell responses against the melanoma. Finally, trained immunity is discussed, and reprogramming events to shape innate immune responses are addressed.
Share